Latest news with #Vgenomics
Time of India
28-05-2025
- Health
- Time of India
Tear-Based Biomarker Identified for early detection of keratoconus
New Delhi: Delhi-based biotech company Vgenomics has partnered with Dr. Shroff's Charity Eye Hospital to validate and commercialize a tear-based biomarker , VSP-2224 , for the early detection of keratoconus , a progressive eye disorder affecting the cornea. VSP-2224, identified in tear fluid using Vgenomics' AI-based discovery platform RgenX-LENS, may help detect the disease earlier, before visible symptoms emerge. Clinical validation of VSP-2224 is underway. The biomarker will also be featured in OcuTear, a rapid diagnostic panel Vgenomics is developing for ocular surface diseases. Commenting on the development, Dr Anil Tiwari said, 'This partnership enables us to translate a tear-based biomarker into a clinically viable diagnostic test, with the potential to further develop it into targeted therapeutics.'
Time of India
21-04-2025
- Health
- Time of India
Vgenomics, Meril Genomics partner to improve access to genomic diagnostics in India
New Delhi: Precision health company Vgenomics announced their partnership with diagnostics and molecular biology provider Meril Genomics to provide complementary advanced genomic diagnostics to hospitals and research centers throughout India. The partnership aims to enhance precision medicine accessibility. Initiatives under this partnership include Non-Invasive Prenatal Testing (NIPT), which addresses the growing risk of chromosomal abnormalities such as Down syndrome, especially among expectant mothers with advanced maternal age. NIPT will facilitate early detection, contributing to safer pregnancies and healthier newborn outcomes across India. In addition, the collaboration introduces targeted Next-Generation Sequencing (tNGS) for Tuberculosis (TB), significantly impacting India's healthcare landscape, where roughly 26% of Global TB cases occur annually. The initiative also includes Whole Exome Sequencing (WES) for diagnosing rare diseases, addressing the needs of approximately 70 million affected individuals in India. Dr. Rahila Sardar, CEO of Vgenomics, said the collaboration reflects a shared commitment to making precision medicine available to more patients, more efficiently.
